Abstract 576P
Background
As third-generation EGFR tyrosine kinase inhibitors (TKIs) have become the frontline treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC), heterogenous responses are commonly observed. This study aimed to investigate the influence of clonal architecture involving EGFR and co-occurring genetic mutations on the response to EGFR-TKIs.
Methods
We gathered a large, homogenous cohort of treatment-naive patients with advanced EGFR-mutant NSCLC who underwent tissue next-generation sequencing (NGS) and received first-line treatment with third-generation EGFR-TKI. Variant allele frequency (VAF) from NGS was normalized based on copy numbers of genes. The VAF of each mutation relative to the maximum VAF in each sample was computed to determine clonality.
Results
A total of 160 eligible patients were enrolled at SYSUCC from January 2019 to January 2023. The aberrant TP53 gene was the most frequent co-alteration, accounting for 68.1% of total cases. EGFR (51.9%) was the most common gene occupying the maximum VAF, followed by TP53 (28.8%), RBM10 (4.4%), RB1 (1.9%), and PIK3CA (1.3%). Both EGFR and TP53 mutations exhibited potential as dominant or subordinate clones in advanced NSCLC. Notably, EGFR-mutant patients receiving first-line third-generation EGFR-TKIs demonstrated significantly prolonged progress-free survival (PFS) when EGFR dominance clone prevailed over EGFR sub-clonal status (median PFS: 22.0m VS. 15.0m, P=0.008). Conversely, TP53 dominance clone correlated with diminished treatment outcomes compared to TP53 sub-clonal cases (median PFS: 15.1m VS. 17.7m, P=0.05). Multivariate analysis confirmed EGFR clonality and TP53 clonality as independent predictors of EGFR-TKI response. Moreover, the clinical impact of EGFR and TP53 clonality was validated in an independent cohort.
Conclusions
Our proof-of-concept study illuminates the clinical significance of both EGFR and TP53 clonality in EGFR-mutant patients with advanced NSCLC who received first-line third-generation EGFR-TKIs. EGFR or TP53 mutations exhibit potential as dominant or subordinate clones, intricately linked to the efficacy of third-generation EGFR-TKIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract